• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Anal Biochem. Author manuscript; available in PMC Oct 2, 2006.
Published in final edited form as:
PMCID: PMC1586112
NIHMSID: NIHMS12401

SEC-MALLS ANALYSIS OF HYALURONAN SIZE DISTRIBUTIONS MADE BY MEMBRANE-BOUND HYALURONAN SYNTHASE

Abstract

SEC-MALLS analyses of E. coli membranes expressing Streptococcus equisimilis hyaluronan synthase (seHAS) demonstrated an inherent artifact (10–100 MDa) that co-eluted with HA, and skewed the apparent weight-average mass of HA to erroneously high values. Briefly heating samples to 65–75°C eliminated this artifact and increased the yield of recovered HA, due to the release of HA chains that were attached to membrane-bound HAS. Inclusion of alkaline phosphatase, which removed UDP produced during the reaction, improved the linearity of HA synthesis - even at high substrate utilization. Surprisingly, addition of EDTA, to chelate Mg+2 ions, did not completely stop the HAS reaction at 30°C or at 4°C. The best conditions for stopping the reaction without altering SEC-MALLS profiles of the product HA were to chill samples on ice in the presence of both EDTA and UDP. Even with excess substrate, the maximum size of product HA decreased as the enzyme concentration increased. Therefore, the maximum HA size made by HAS was determined by extrapolation to zero enzyme concentration. Using the above conditions, membrane-bound seHAS synthesized a cohort of HA products that steadily increased in weight-average molar mass, reaching a final maximal steady-state size of 4–6 MDa within 2–4 hours.

Keywords: streptococcal, hyaluronan synthase, light scattering, size distribution, membranes, molar mass

Introduction

In order to understand the mechanisms by which HAS1 enzymes can regulate HA product size, it is necessary to characterize the HA size distributions created by HASs [1 ] in isolated membranes, intact cells, and tissue samples. Although several groups have reported the average HA masses made by various wildtype or mutant HAS proteins in membranes or cells [27], these studies have generally used either gel filtration [8 ] or gel electrophoresis techniques [9,10 ] to assess apparent HA size. One of the best current techniques for determining the molecular masses of heterogeneous polymers, such as HA, is size exclusion chromatography coupled to multiangle laser light scattering (SEC-MALLS). The SEC-MALLS technique provides accurate and informative data regarding the size distribution of polydisperse HA samples without the need for calibration standards [1114]. Although many investigators have used light scattering techniques to study HA since the 1950s [1521], we found no reports in the literature in which MALLS has been utilized to analyze the size distribution of HA products made by membrane-bound HAS.

The three human HAS isozymes (HAS1, HAS2, and HAS3) make different HA size distributions in crude membranes in vitro [2,3 ], and in live Xenopus laevis embryos, HAS1 and HAS2 make different size HA [4]. Based on these reports, it is possible under different physiological conditions in vivo that HASs can make HA molecules of different masses that in turn have different size-specific biological functions. These exciting and important possibilities were first recognized when HA oligosaccharides were shown to be angiogenic [22]. Thus, it would be very useful and relevant to use SEC-MALLS to characterize HA size distributions in biologically relevant samples. Here, we report the identification of, and experimental solutions to, several problems and potential artifacts arising from how HA samples made by membranes containing HAS are processed for SEC-MALLS analysis.

Materials and Methods

Materials

Uridine 5′-diphospho-N-acetylglucosamine (UDP-GlcNAc), uridine ′- diphosphoglucuronic acid [UDP-GlcUA), uridine 5′- diphosphate (UDP) and Stainsall were from Sigma-Aldrich Corporation (St. Louis, MO). Uridine 5′- diphospho-[14C]glucuronic acid (UDP-[14C]GlcUA) was from Perkin Elmer Life and Analytical Sciences (Boston, MA). Calf intestinal alkaline phosphatase, molecular biology grade, was from EMD Biosciences, Inc. (La Jolla, CA). Agarose (GenePure LE) was from ISC BioExpress (Kaysville, UT). Commercial HA preparations used as standards were from Genzyme (Boston, MA) or Lifecore (Chaska, MN). Select-HA and Mega-HA standards of well defined size were obtained from Hyalose (Oklahoma City, OK). Size exclusion chromatography used either TSK-GEL G6000PWxl columns from TOSOH Bioscience LLC (Montgomeryville, PA) or PL Aquagel-OH 60 columns from Polymer Laboratories, Inc. (Amherst, MA). The DAWN DSP Laser Photometer and the OptiLab DSP Interferometric Refractometer were from Wyatt Technology Corporation (Santa Barbara, CA). The auto-sampler was a Waters 717plus from Waters Corp. (Milford, MA).

HA Synthesis

Membranes were prepared and assayed for HAS activity as described by Tlapak-Simmons et al. [23]. HAS activity was assessed by measuring HA production either by utilization of UDP-[14C]GlcUA or by integration of refractive index values obtained by SEC-MALLS analysis of non-radiolabeled samples. Final volumes for the radioactive and MALLS assay samples were 0.1 and 0.5–1.0 mL, respectively. Membranes were suspended by brief sonication at 0°C and added to 2 ml microcentrifuge tubes to a final concentration of 0.01 – 0.02 mg/ml total membrane protein in assay buffer containing 18.75 mM sodium phosphate and 6.25 mM potassium phosphate, pH 7.0, 75 mM NaCl, 2% (v/v) glycerol, 0.1mM EDTA, 1.0 mM DTT, 0.1 mM PMSF, 1.0 μM Pepstatin, and 2 μM Leupeptin. UDP-GlcUA and UDP-GlcNAc were added to 1 mM final concentration, the mixture incubated at 30°C for 10 min, and calf intestinal alkaline phosphatase was added to a final concentration of 0.02 U/μL. For the radiolabel assays, UDP-[14C]GlcUA was also added to 0.7 μM. The synthesis reactions were then initiated by the addition of MgCl2 to a final concentration of 20 mM and incubation for up to 8 hr at 30°C in a vibrating Taitec mixer (San Jose, CA). Unless noted otherwise, synthesis was terminated by adding EDTA and UDP to final concentrations of 40 mM and 10 mM, respectively, and chilling on ice for ~20 min and then heating in a 100°C bath (sand) to inactivate the phosphatase. The same heat treatment was used for MALLS samples. The duration of heating was 1 min per 0.1 mL volume and the final temperature of treated samples was 65–75°C. Radio-labeled samples were quenched by adding SDS to 2% and then analyzed by paper chromatography [23]. If SEC-MALLS samples were stored at 4°C for more than a few hours, then the heat treatment was repeated prior to injection.

SEC-MALLS

Analyses were performed by chromatographic separation of samples using either one TSK-Gel G6000PWXL column (TOSOH-BIOSEP) or one or two (in series) PLaquagel-OH60 (Polymer Labs) columns at 22°C at a flow rate of 0.4 – 0.5 ml/min in 50 mM sodium phosphate, pH 7.0, 150 mM NaCl, 0.05% sodium azide. MALLS analysis of a sample was performed continuously on the column eluate, as it passed through a DAWN DSP Laser Photometer in series with an OPTILAB DSP Interferometric Refractometer (both from Wyatt Technologies, Inc). Data were analyzed using Astra v4.73, a dn/dc value of 0.153 (24), an A2 value of 0.0023 (25), and either 1st order Zimm or 2nd order Berry fits, depending on the size of the HA being analyzed. In our experience, 1st order Zimm fits had less uncertainty in analysis of data for HA of < 2 MDa, whereas 2nd order Berry analysis of data for HA of > 2 MDa gave better fits. Samples (200 μl) in microcentrifuge tubes were incubated in a 100°C bath for 2 min prior to injection; the solution temperature after 2 min was ~65°C, as determined with a thermistor. Column performance was monitored by the routine analysis of a commercial HA used as a reference standard. Regular washing of the column with 0.1% SDS in water (2 ml) restored column performance and HA fractionation, and minimized artifacts that were probably due to accumulation of lipid on the column. In our experience, high HA concentrations should also be avoided when using SEC-MALLS, since artificially high mass values may occur, possibly due to chain entanglement. Unlike gel electrophoresis techniques, however, MALLS inherently provides concentration data so that one can easily monitor samples and stay below an appropriate concentration to minimize concentration-dependent artifacts (e.g. we routinely inject samples that are ≤ 0.05 mg/ml HA).

Agarose gel electrophoresis was performed essentially as described by Lee and Cowman (9) using 0.8% (w/v) gels and ~3 μg HA per lane (estimated from MALLS results). Samples were precipitated with 3 volumes of ethanol at −20°C, and redissolved in the running buffer, which contained 1 mM EDTA, 40 mM trishydroxymethylamino methane, 100 mM sodium acetate, pH 7.6. Electrophoresis was at 80V for 2.5–3 hr and the gels were stained overnight with 0.005% Stainsall in 50% ethanol. Gels were destained by washing and exposure to light. Digital images were captured as jpeg files using a FluoroChem FC from Alpha Innotech Corp (San Leandro, CA).

Results

Our initial goal was to utilize SEC-MALLS to determine the rate of HA synthesis and the rate of HA product size increase by recombinant seHAS in membranes. Since MALLS techniques are notoriously sensitive to debris, protein aggregation, and other light scattering artifacts, most investigators have not tried to assess HAS function in native membranes using this technique. In fact, we could find no reports in the PubMed database in which light scattering had been used to analyze HA made by any HAS in membrane preparations. Given that MALLS is one of the best methods to assess HA molar mass and size distributions, we sought to eliminate potential artifacts in order to use this technique to obtain reliable data about HAS function in membranes.

Elimination of an artifact associated with SEC-MALLS analysis of membranes

The first problem we encountered was the discovery of large molecular mass material that was associated with the use of membrane suspensions. This material had an apparent mass of 10 –100 MDa by MALLS, even though it eluted at a SEC position corresponding to HA of 300 – 500 kDa, and gave rise to increasing, rather than decreasing, apparent HA mass as the chromatographic elution progressed (light scattering profiles in Fig. 1A). However, we discovered that this artifact could be eliminated or minimized by brief heating of membrane samples in a 100°C bath until the temperature was 65–75°C. The high molar mass material in heat-treated samples was HA, since it was not present in samples lacking UDP-sugars and was completely eliminated by treatment with Streptomyces hyaluronidase (not shown). The utility of the heat treatment step was greatest if the treatment was just prior to sample analysis (i.e. within a few hours). Samples that were heat treated, stored for days at 4°C and then analyzed, showed increasing reappearance of the artifact noted above (not shown).

Figure 1
Heat treatment of membranes eliminates a large mass artifact and releases HA chains bound to HAS

Using this simple heat treatment protocol, we also investigated whether the addition of membranes containing HAS (without UDP-sugars) to highly purified commercial HA of different Mw had any effect on the SEC-MALLS analysis of the HA (Table 1). Without heat treatment, the presence of exogenous membranes interfered with the analysis as expected from Fig 1 (not shown), but the brief heat treatment allowed the acquisition of data that were essentially as reproducible and accurate as that obtained in the absence of membranes. The assessments of weight-average molar masses were only a few percent different for the heat-treated samples in the presence of membranes. There were no statistically significant differences between the pure HA samples (without membranes and not heated) and those analyzed in the presence of membranes after heat treatment. Importantly, the heat treatment in the presence of added membranes also had no effect on the experimentally determined Mw values for HA preparations with a wide range of different size distributions. Thus, the presence of membranes per se, does not preclude the ability to obtain high quality data on HA molar mass distributions by SEC-MALLS.

Table 1
Effect of heat treatment in the presence of membranes on the size and recovery of commercial HA

Heat treatment increases HA yield by releasing membrane-bound HA chains

We also found that additional HA was obtained (e.g. >100% more depending on the initial synthesis period), based on the mass of HA calculated from refractive index values (Fig. 1B), after the brief heating step to minimize the large mass artifact. With the exception of the enzyme from Pasteurella multocida, which is nonprocessive [26], all HASs appear to retain and tightly bind their growing HA chains until they are released. Once an HA chain is released, it is “completed” in that it can apparently no longer be bound and extended by another HAS. Thus, although the HA chain release process may determine the distribution of product HA sizes made by a HAS, the conditions that facilitate or hinder HA chain release from HASs have not been identified.

Based on previous HAS studies, one would expect that very early during a synthesis reaction, virtually all HA chains would be at various stages of elongation and still bound to HAS; very little of the total HA would be free. In contrast, at much later stages of a synthesis reaction only a small fraction of total HA would still be bound to HAS and thus membrane-associated, and a large fraction would be free HA chains that had continuously accumulated as they were released. These expectations were tested and verified by comparing the total HA yield for parallel samples, analyzed with and without the heat treatment, as a function of incubation time during the synthesis reaction (Fig. 2A). For samples taken early during the reaction period, the HA yield was greatly increased by heating (e.g. 217% at 15 min), whereas at later reaction times the increase was very modest (e.g. 17% at 4 hr). Overall HA recovery, assessed by MALLS, steadily increased with time, whether the analysis was of heated or untreated samples (Fig. 2B and 2C). The biphasic increase and then decrease in the enhanced recovery of HA by the heat treatment (Fig. 2A) is expected as HA chains are initiated and enzyme-bound, but later released by the active membrane-bound HAS molecules in the sample.

Figure 2
The relative increase in HA recovery by heat treatment of membranes is dependent on the duration of HA synthesis

Additional experiments in which samples were heated or centrifuged to pellet membranes confirmed that the heat treatment released HA from membranes (not shown). The finding that the HAS-bound HA is not recovered in SEC-MALLS analysis unless samples are heated, is most likely due to the binding (and thus loss) of membranes containing attached HA to the column support. As noted in Methods, this accumulated material is readily removed by washing the column periodically with SDS. The kinetic profile obtained for the heated samples was also a better estimate of the continuous steady synthesis of HA, than the kinetic profile of the untreated samples (Fig. 2C). These latter unheated samples showed a pronounced apparent kinetic lag, which actually reflected the failure to recover the HA bound to HAS in these samples.

Stopping the HAS reaction to allow stable storage of samples

Unexpected results were also obtained in kinetic analyses of membrane-bound HAS to determine how HA size changed with time of synthesis and how long it took to achieve a steady-state size distribution. Such analyses require conditions that quickly terminate the enzyme reaction, such as decreasing the temperature or chelating the required Mg+2 ions. HAS assays that are to be analyzed by paper chromatography are normally terminated by addition of SDS to a final concentration of 2% (w/v), but this approach cannot easily be used when performing SEC-MALLS analyses, due to interference caused by the light scattering of SDS micelles. Thus, our goal was to assess other possible conditions to stop the HA synthase reaction, in order to validate subsequent kinetic studies.

Unfortunately, freezing samples at −20°C to stop the enzyme reaction was not useful, because this treatment generated a high molar mass artifact, which subsequent heat treatment did not remove (not shown). Many investigators might reasonably assume that HA synthesis will be negligible at 4°C or in the presence of chelators and use such conditions to study HA size distributions or the kinetics of HA accumulation. We tested these conditions for their ability to give stable samples; that is, stored samples with no time-dependent changes in HA amount or size distribution after “quenching” the reaction. At 30°C, a normal assay temperature, EDTA (in large molar excess over Mg+2 ions) did not stop the synthase reaction (Fig. 3A). HAS-containing membranes in the presence of UDP-sugar substrates also could not just be chilled and stored at 4°C to stop HA synthesis, and more surprisingly, seHAS was still active at 4°C in the presence of EDTA (Fig. 3B). Under the latter conditions, the continuous slow synthesis of HA occurred over a period of days (Fig. 3C). However, HAS activity was successfully quenched in the presence of both EDTA and UDP at 4°C (Figs. 3B and 3C).

Figure 3
The HAS reaction is not completely stopped by treatment with EDTA or low temperature

Accumulating UDP product decreases the rate of synthesis and the apparent HA product size distributions made by HAS

The streptococcal and eukaryotic HASs, whose activities have been characterized kinetically, are all inhibited by exogenous UDP [2628]. This was, in fact, the rationale for including UDP in the above enzyme quench procedure. Since the UDP concentration steadily increases as this product is generated by utilization of the two UDP-sugars during HA synthesis, the rate of HA synthesis will decrease progressively (Fig. 4). Although this decreased synthesis rate is sometimes attributed to depletion of the substrates, it can also be due to the build-up of UDP because the addition of alkaline phosphatase, which hydrolyzes nucleotides, substantially restored the kinetic linearity of these reactions.

Figure 4
Continuous removal of UDP enhances the linearity of HA synthesis by HAS

The apparent HA product size decreases as the ratio of enzyme to substrate increases

In addition to HA-product size being dependent on the duration of synthesis, we found a very significant decrease in HA size with increasing HAS concentration (Fig. 5A). The same result was observed whether the analysis was by MALLS or gel electrophoresis. Even at higher substrate concentrations (e.g. 4 mM each UDP-sugar), there was an inverse correlation between the amount of membrane protein used and HA size (not shown). Extrapolation of these curves to zero-HAS content (Fig 5B) eliminated any artifact due to the amount of HAS used, and gave the theoretical maximum HA mass that could be made by that particular HAS under the experimental conditions.

Figure 5
The apparent size of HA products is inversely related to the amount of HAS used

We finally used the kinetic quenching conditions noted above, inclusion of alkaline phosphatase, and SEC-MALLS to assess the time-dependent changes in HA-product size distribution (Fig 6A). As expected the weight-average molar mass of HA products increased with time, reflecting HA chain growth. A steady-state HA size distribution was obtained after 2–4 hours. The same result was confirmed in experiments to assess changes in HA size by agarose gel electrophoresis (Fig. 6B). These results were also very consistent with those in Fig. 2A, which showed that increased HA recovery, by heating to dissociate HA from HAS, occurred for up to ~2 hours. The results indicate that each HAS may be associated with a growing HA chain for more than an hour before the HA chain is released and the enzyme initiates synthesis of a new HA chain. The HA products made in subsequent rounds of chain synthesis are distributed as a smear trailing below the major band (as in Fig 6B, lane 6). In three different experiments, the percent of total HA that was in the tailing region increased from 27 ± 4 at 30 min to 43 ± 1 at 480 min.

Figure 6
Kinetic analysis of HA product size distributions

Discussion

We have developed procedures to use SEC-MALLS to study the molar mass distributions of HA made by HA synthases in membranes. This approach has not been reported previously, due to the extreme sensitivity of MALLS to contaminating particles and debris. Nonetheless, there is a great interest in accurate analysis of HA size in biologically relevant samples. Several findings should be noted in terms of compromising or confounding effects in trying to use MALLS for these analyses.

First, any analyses would not have been possible without the ability of a simple heat treatment to eliminate the membrane-related large mass artifact (Fig 1). A second surprising potential artifact in performing kinetic and product size analyses was the finding that addition of excess EDTA alone, to chelate Mg+2 ions, was insufficient to terminate the synthase reaction, even at 4°C. Thus, the residual low activity of HAS enzymes at low temperature and in the presence of chelators, such as EDTA, may compromise the results of studies that utilize these conditions, rather than SDS, to quench the reaction. Since freezing membrane-containing samples could not be used due to additional artifacts, we ultimately determined that the best way to stop the HA synthase reaction was to add UDP and EDTA, and chill the samples on ice. SEC-MALLS profiles and HA product size distributions were stable at 4°C in the presence of both UDP and EDTA.

A third surprising finding was related to the amount of HAS assayed, which has been overlooked by most investigators, including our group, in past studies. As the HAS concentration increased, the HA-product size decreased (Fig. 5A). Since one needs to use an amount of HAS activity that gives a good signal, this effect may sometimes be unavoidable. This negative correlation of product size with increasing HAS/substrate ratio might be explained by the competition among individual HAS molecules for precursors to sustain elongation of their HA chains at a certain rate. Although the overall rate of HA synthesis (e.g. glycoside bonds made per sec) may be nearly identical between two samples with slightly different HAS concentrations and the same high UDP-sugar concentrations, the sample with fewer active HAS molecules is able to make longer HA chains on average than the one with more HASs. Whatever the reason, this counter-intuitive effect results in an inverse linear relationship (Fig. 5B) between observed weight-average HA mass and HAS protein concentration, at least at lower HAS concentrations.

One reason for this above effect may be related to the fact that polysaccharide synthases are unusual and rare enzymes. They have not been extensively studied, compared to nucleic acid polymerases that use a template or to enzymes that catalyze a typical one or two substrate reaction and then release a product after each round of catalysis. The Class I HASs act on the product of each previous cycle and this new substrate is always different because it is one sugar longer than the previous product/substrate. Another possible confounding effect is that at higher HAS concentration, growing HA chains on different membrane fragments may be more likely to interact (e.g. forming nested helices) and consequently slow down the rate of chain elongation. In this situation, a HAS molecule might have to translocate an HA cluster, whose inertial resistance would be greater than that of a single HA chain [5].

A fourth problem was that during the relatively long times required to achieve steady-state HA size distributions, HA synthesis was not always linear. This was solved, however, by including alkaline phosphatase in the HAS reactions, which were then linear for at least 8 h, even when >50% of substrate was converted to HA (Fig. 5). Kinetic inhibition is greatly delayed, because the continuous hydrolysis of UDP by the phosphatase prevents its build-up. When inhibition finally occurs in the presence of alkaline phosphatase, it is because the substrates are depleted to a much greater extent - to the point where substrate concentrations drop to < Km values and enzyme velocity is substrate-limited. The significance of including alkaline phosphatase when HA size is to be studied by MALLS or electrophoresis is two-fold. First, HA chain elongation can continue longer without feedback inhibition due to UDP buildup, and second, without addition of phosphatase a maximal steady-state HA size distribution may not occur before HA synthesis is inhibited.

Based on the above considerations for appropriate experimental conditions, we have adopted the following approach to determine the largest HA product size that can be made by a HAS. (i) Alkaline phosphatase is routinely included to eliminate feedback inhibition by UDP and enhance linearity of HA synthesis. (ii) Samples are quenched by adding UDP and EDTA to final concentrations of 10 mM and 40 mM, respectively, chilling on ice, and then heating briefly to inactivate the phosphatase. (iii) The stored samples are heated to 65–75 °C just prior to injection for SEC-MALLS analysis. (iv) The time-dependence for the increase in average HA size is determined to ensure that a steady-state size distribution is obtained. (v) The kinetics of HA product size increase is determined for 3–4 different concentrations of HAS-containing membranes in the presence of sufficient alkaline phosphatase to maintain linearity of HA synthesis. (vi) Finally, the Mw (or Mn) values obtained from SEC-MALLS analyses of the 3–4 samples are plotted versus membrane protein (HAS content does not need to be known), and the zero-intercept then calculated to determine the maximum Mw of HA products that can be made by the HAS or HAS variants being studied. A key point is that in an analysis of HA size, investigators need to consider and separately assess both the rate of HA synthesis (i.e. the total amount of sugar incorporated into HA products) and the rate of HA product size increase.

The results indicate that 1–2 hours, seHAS molecules release their HA chains and initiate synthesis of new HA chains. However, the subsequent rounds of HA synthesis are not associated with a cohort of similar-sized HA, because the initial synchronization of the enzyme reactions is lost. Samples in which HAS synthesizes multiple rounds of HA chains have a higher percent of HA products that are smaller than the maximum product size (e.g. lanes 5 and 6 versus lanes 1–3 in Fig 6B) and distributed over a broad range of sizes, as typically observed for naturally occurring HA samples. The synchronization of HA product sizes observed for seHAS probably occurs because the recombinant enzyme is not associated with endogenous HA, since E. coli SURE cells lack the substrate UDP-GlcUA (29).

In this report, we describe some of the unexpected obstacles encountered in kinetic studies to determine simultaneously the rate of HA synthesis and the size distribution of HA made by membrane preparations expressing a HAS. Many of these potential artifacts will be problematic and could make it difficult to obtain valid results, whether one uses gel electrophoresis, SEC alone or SEC-MALLS to analyze HA size. Fortunately, we found reasonable conditions to minimize these confounding effects, so that meaningful data could be obtained about HA size. Consequently, we and other investigators should now be better able to utilize the power of light scattering analysis to study how HA product size may be regulated by HA synthases.

Acknowledgments

This research was supported by National Institutes of Health Grant GM35978 from the National Institute of General Medical Sciences. We thank Jennifer Acuna and Jennifer Griffin for the preparation of membranes and general technical assistance.

Footnotes

1Abbreviations: HA, hyaluronic acid, hyaluronate, hyaluronan; HAS, HA synthase; seHAS, Streptococcus equisimilis HAS; PBS, phosphate buffered saline; SEC-MALLS, size exclusion chromatography - multiangle laser light scattering.

References

1. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem. 1997;272:13997–14000. [PubMed]
2. Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, Shinomura T, Hamaguchi M, Yoshida Y, Ohnuki Y, Miyauchi S, Spicer AP, McDonald JA, Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999;274:25085–25092. [PubMed]
3. Brinck J, Heldin P. Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res. 1999;252:342–351. [PubMed]
4. Koprunner M, Mulleggerl J, Lepperdinger G. Synthesis of hyaluronan of distinctly different chain length is regulated by differential expression of Xhas1 and 2 during early development of Xenopus laevis. Mech Dev. 2000;90:275–278. [PubMed]
5. Heldermon C, Kumari K, Tlapak-Simmons V, Weigel PH. Streptococcal hyaluronan synthases and the synthesis of designer hyaluronan. In: Abatelangelo G, Weigel PH, editors. New Frontiers in Medical Sciences: Redefining Hyaluronan. Elsevier Science, B.V.; Amsterdam: 2000. pp. 41–50.
6. Kumari K, Tlapak-Simmons V, Baggenstoss BA, Weigel PH. The streptococcal hyaluronan synthases are inhibited by sulfhydryl modifying reagents but conserved cysteine residues are not essential for enzyme function. J Biol Chem. 2002;277:13943–13951. [PubMed]
7. Pummill PE, DeAngelis PL. Alteration of polysaccharide size distribution of a vertebrate hyaluronan synthase by mutation. J Biol Chem. 2003;278:19808–19814. [PubMed]
8. Beaty NB, Tew WP, Mello RJ. Relative molecular weight and concentration determination of sodium hyaluronate solutions by gel-exclusion high-performance liquid chromatography. Anal Biochem. 1985;147:387–395. [PubMed]
9. Lee HG, Cowman MK. An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution. Anal Biochem. 1994;219:278–287. [PubMed]
10. Armstrong SE, Bell DR. Measurement of high-molecular-weight hyaluronan in solid tissue using agarose gel electrophoresis. Anal Biochem. 2002;308:255–264. [PubMed]
11. Wyatt PJ. Multiangle light scattering combined with HPLC. LC•GC. 1997;15:160–168.
12. Wyatt PJ. Light scattering and the absolute characterization of macromolecules. Analytica Chimica Acta. 1993;272:1–40.
13. Knobloch JE, Shaklee PN. Absolute molecular weight distribution of low-molecular-weight heparins by size-exclusion chromatography with multiangle laser light scattering detection. Anal Biochem. 1997;245:231–241. [PubMed]
14. Girod S, Baldet-Dupy P, Maillols H, Devoisselle JM. On-line direct determination of the second virial coefficient of a natural polysaccharide using size-exclusion chromatography and multi-angle laser light scattering. J Chromatogr A. 2002;943:147–152. [PubMed]
15. Blumberg BS. Light-scattering studies on hyaluronic acid. Science. 1954;120:432–433. [PubMed]
16. Laurent TC, Gergely J. Light scattering studies on hyaluronic acid. J Biol Chem. 1955;212:325–333. [PubMed]
17. Ogston AG. Measurement by light scattering of the exclusion of protein by hyaluronic acid. Fed Proc. 1966;25:1122–1123. [PubMed]
18. Hallett FR, Gray AL. Quasi-elastic light scattering studies of hyaluronic acid solutions. Biochim Biophys Acta. 1974;343:648–655. [PubMed]
19. Reihanian H, Jamieson AM, Tang LH, Rosenberg L. Hydrodynamic properties of proteoglycan subunit from bovine nasal cartilage. Self-association behavior and interaction with hyaluronate studied by laser light scattering. Biopolymers. 1979;18:1727–1747. [PubMed]
20. Reed CE, Li X, Reed WF. The effects of pH on hyaluronate as observed by light scattering. Biopolymers. 1989;28:1981–2000. [PubMed]
21. Hokputsa S, Jumel K, Alexander C, Harding SE. A comparison of molecular mass determination of hyaluronic acid using SEC/MALLS and sedimentation equilibrium. Eur Biophys J. 2003;32:450–456. [PubMed]
22. West DC, Hampson IN, et al. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228:1324–1326. [PubMed]
23. Tlapak-Simmons VL, Baggenstoss BA, Kumari K, Heldermon C, Weigel PH. Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis. J Biol Chem. 1999;274:4246–4253. [PubMed]
24. Sheehan JK, Arundel C, Phelps CF. Effect of the cations sodium, potassium and calcium on the interactions of hyaluronate chains: a light scattering and viscometric study. Int J Biol Macromol. 1983;5:222–228.
25. Ghosh S, Khobal I, Zanette D, Reed WF. Conformational contraction and hydrolysis of hyaluronate in sodium hydroxide solutions. Macromolecules. 1993;26:4684–4691.
26. DeAngelis PL. Microbial glycosaminoglycan glycosyltransferases. Glycobiol. 2002;12:9R–16R. [PubMed]
27. Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life. 2002;54:195–199. [PubMed]
28. Weigel PH. Functional characteristics and catalytic mechanisms of the bacterial hyaluronan synthases. IUBMB Life. 2002;54:201–211. [PubMed]
29. DeAngelis PL, Papaconstantinou J, Weigel PH. Molecular cloning, identification and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes. J Biol Chem. 1993;268:19181–19184. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...